SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun strengthens on receiving USFDA’s nod for Ibuprofen Tablets

01 Jun 2017 Evaluate

Strides Shasun is currently trading at Rs. 957.95, up by 52.65 points or 5.82% from its previous closing of Rs. 905.30 on the BSE.

The scrip opened at Rs. 903.05 and has touched a high and low of Rs. 953.50 and Rs. 903.05 respectively. So far 45,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1259.00 on 03-Feb-2017 and a 52 week low of Rs. 848.50 on 24-May-2017.

Last one week high and low of the scrip stood at Rs. 967.95 and Rs. 875.00 respectively. The current market cap of the company is Rs. 8,560.00 crore.

The promoters holding in the company stood at 31.09%, while Institutions and Non-Institutions held 48.89% and 20.02% respectively.

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Ibuprofen Tablets USP, 200 mg (OTC). The US market for Ibuprofen Tablets USP 200 mg (OTC) is around $520 Million. The approval further strengthens company’s fast growing global OTC franchise. The product will be marketed by Strides Pharma Inc in the US Market under its OTC brand Nuprin.

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).

Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.


Strides Pharma Scien Share Price

995.90 -4.80 (-0.48%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×